Cholera remains a major global public health problem, for which oral cholera vaccines (OCVs) being a valuable strategy. Patients, who have recovered from cholera, develop antibody responses against LPS, cholera toxin (CT), toxin-coregulated pilus (TCP) major subunit A (TcpA) and other antigens; thus, these responses are potentially important contributors to immunity against
Vibrio cholerae
infection. However, assessments of the efficacy of current OCVs, especially inactivated OCVs, have focused primarily on O-antigen-specific antibody responses, suggesting that more sophisticated strategies are required for inactivated OCVs to induce immune responses against TCP, CT, and other antigens. Previously, we have shown that the
toxT
-139F allele enables
V. cholerae
strains to produce CT and TCP under simple laboratory culture conditions. Thus, we hypothesized that
V. cholerae
strains that express TCP via the
toxT
-139F allele induce TCP-specific antibody responses. As anticipated,
V. cholerae
strains that expressed TCP through the
toxT
-139F allele elicited antibody responses against TCP when the inactivated bacteria were delivered via a mouse model. We have further developed TCP-expressing
V. cholerae
strains that have been used in inactivated OCVs and shown that they effect an antibody response against TcpA in vivo, suggesting that
V. cholerae
strains with the
toxT
-139F allele are excellent candidates for cholera vaccines.